Nymox Pharma (NASDAQ: NYMX) announced long-term clinical trial results from the Company's NX-1207 Phase 2 prostate cancer study NX03-0040. The ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE